GB1485676A - Pharmaceutical formulations containing l-dopa or derivatives thereof - Google Patents
Pharmaceutical formulations containing l-dopa or derivatives thereofInfo
- Publication number
- GB1485676A GB1485676A GB46402/75A GB4640275A GB1485676A GB 1485676 A GB1485676 A GB 1485676A GB 46402/75 A GB46402/75 A GB 46402/75A GB 4640275 A GB4640275 A GB 4640275A GB 1485676 A GB1485676 A GB 1485676A
- Authority
- GB
- United Kingdom
- Prior art keywords
- alanine
- diacetoxyphenyl
- dopa
- dipivaloyloxyphenyl
- methylethenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title abstract 5
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229960003767 alanine Drugs 0.000 abstract 5
- -1 benzyl ester Chemical class 0.000 abstract 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 abstract 2
- WQNHWIYLCRZRLR-UHFFFAOYSA-N 2-(3-hydroxy-2,5-dioxooxolan-3-yl)acetic acid Chemical compound OC(=O)CC1(O)CC(=O)OC1=O WQNHWIYLCRZRLR-UHFFFAOYSA-N 0.000 abstract 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 abstract 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 abstract 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 abstract 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000002702 enteric coating Substances 0.000 abstract 1
- 238000009505 enteric coating Methods 0.000 abstract 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 abstract 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 abstract 1
- 159000000001 potassium salts Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 abstract 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 abstract 1
- 235000017557 sodium bicarbonate Nutrition 0.000 abstract 1
- 229910000029 sodium carbonate Inorganic materials 0.000 abstract 1
- 235000017550 sodium carbonate Nutrition 0.000 abstract 1
- 239000011975 tartaric acid Substances 0.000 abstract 1
- 235000002906 tartaric acid Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP49131304A JPS5157813A (en) | 1974-11-14 | 1974-11-14 | Ll dooba mataha sonojudotaiseizaino seiho |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1485676A true GB1485676A (en) | 1977-09-14 |
Family
ID=15054818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB46402/75A Expired GB1485676A (en) | 1974-11-14 | 1975-11-10 | Pharmaceutical formulations containing l-dopa or derivatives thereof |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US3961041A (enExample) |
| JP (1) | JPS5157813A (enExample) |
| CA (1) | CA1047928A (enExample) |
| DE (1) | DE2551280A1 (enExample) |
| ES (1) | ES442579A1 (enExample) |
| FR (1) | FR2290912A1 (enExample) |
| GB (1) | GB1485676A (enExample) |
| IT (1) | IT1069069B (enExample) |
| NL (1) | NL7513370A (enExample) |
| SE (1) | SE7512740L (enExample) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2130087A (en) * | 1982-09-22 | 1984-05-31 | Dr Joachime Helbig | Pharmaceutical oral dosage forms of an active agent capable of forming or releasing bicarbonate ions |
| EP0228253A1 (en) * | 1985-12-30 | 1987-07-08 | Merck & Co. Inc. | Rectally absorbable form of L-dopa |
| US4786505A (en) * | 1986-04-30 | 1988-11-22 | Aktiebolaget Hassle | Pharmaceutical preparation for oral use |
| US4853230A (en) * | 1986-04-30 | 1989-08-01 | Aktiebolaget Hassle | Pharmaceutical formulations of acid labile substances for oral use |
| US5286492A (en) * | 1990-05-03 | 1994-02-15 | Reckitt & Colman Products Limited | Method of treatment of Heliobacter pylori infections with triclosan |
| US6280773B1 (en) | 1998-12-29 | 2001-08-28 | Il Yang Pharm. Co., Ltd. | Optimally stabilized microgranule comprising 5-pyrrolyl-2-pyridylmethylsulfinylbenzimidazole derivative |
| US6576258B1 (en) | 1997-07-14 | 2003-06-10 | Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. | Pharmaceutical formulation with controlled release of active substances |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4147768A (en) * | 1976-09-13 | 1979-04-03 | Interx Research Corporation | Enteric coated digoxin and therapeutic use thereof |
| JPS54138128A (en) * | 1978-04-19 | 1979-10-26 | Akiyama Jiyouzai Kk | Double contrast medium for intestine |
| US4289751A (en) * | 1979-06-29 | 1981-09-15 | Merck & Co., Inc. | Effervescent enteric-coated formulation of soluble form of erythromycin and therapeutic use thereof |
| FR2470599A1 (fr) * | 1979-12-07 | 1981-06-12 | Panoz Donald | Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus |
| US4874614A (en) * | 1985-03-25 | 1989-10-17 | Abbott Laboratories | Pharmaceutical tableting method |
| US4863741A (en) * | 1985-03-25 | 1989-09-05 | Abbott Laboratories | Tablet composition for drug combinations |
| EP0252290B1 (en) * | 1986-06-10 | 1992-06-03 | CHIESI FARMACEUTICI S.p.A. | Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof |
| US4983400A (en) * | 1986-06-16 | 1991-01-08 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
| GB8724763D0 (en) * | 1987-10-22 | 1987-11-25 | Aps Research Ltd | Sustained-release formulations |
| US4942039A (en) * | 1989-05-09 | 1990-07-17 | Miles Inc. | Effervescent analgesic antacid composition having reduced sodium content |
| US5607969A (en) * | 1992-12-24 | 1997-03-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | L-DOPA ethyl ester to treat Parkinson's disease |
| US5354885A (en) * | 1992-12-24 | 1994-10-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Process for preparing ethyl ester of L-DOPA |
| US20040151768A1 (en) * | 1997-07-23 | 2004-08-05 | Chiesi Farmaceutici S.P.A. | Pharmaceutical compositions containing an effervescent acid-base couple |
| US7060734B1 (en) | 1997-09-09 | 2006-06-13 | Alza Corporation | Pharmaceutical coating composition and method of use |
| JP2001515855A (ja) * | 1997-09-09 | 2001-09-25 | アルザ・コーポレーション | 薬剤コーティング組成物と使用方法 |
| DE69910183T2 (de) * | 1998-03-11 | 2004-06-03 | Grelan Pharmaceutical Co., Ltd., Hamura | Darmlösliche sprudelnde zusammensetzungen |
| US20030091629A1 (en) * | 1998-03-27 | 2003-05-15 | Cima Labs Inc. | Sublingual buccal effervescent |
| US20030118645A1 (en) * | 1998-04-29 | 2003-06-26 | Pather S. Indiran | Pharmaceutical compositions for rectal and vaginal administration |
| US6974590B2 (en) | 1998-03-27 | 2005-12-13 | Cima Labs Inc. | Sublingual buccal effervescent |
| US6576250B1 (en) | 1998-03-27 | 2003-06-10 | Cima Labs Inc. | Pharmaceutical compositions for rectal and vaginal administration |
| US6350470B1 (en) * | 1998-04-29 | 2002-02-26 | Cima Labs Inc. | Effervescent drug delivery system for oral administration |
| DE69942205D1 (de) * | 1998-08-13 | 2010-05-12 | Cima Labs Inc | Microemulsionen als feste dosisformen zur oralen verabreichung |
| NZ512030A (en) | 1998-11-10 | 2003-10-31 | Teva Pharma | Process for manufacture of L-dopa ethyl ester |
| CA2350304A1 (en) | 1998-11-10 | 2000-05-18 | Teva Pharmaceutical Industries, Ltd. | Dispersible compositions containing l-dopa ethyl ester |
| AU2005202472B2 (en) * | 1999-04-29 | 2008-12-18 | Cima Labs Inc. | Effervescent drug delivery system for oral administration |
| GB0217056D0 (en) * | 2002-07-23 | 2002-08-28 | Ass Octel | Use |
| CA2548915C (en) * | 2003-12-31 | 2012-10-16 | Cima Labs Inc. | Generally linear effervescent oral fentanyl dosage form and methods of administering |
| MXPA06007453A (es) * | 2003-12-31 | 2007-01-31 | Cima Labs Inc | Forma de dosificacion de opiaceo oral efervescente. |
| US7858121B2 (en) | 2003-12-31 | 2010-12-28 | Cima Labs, Inc. | Effervescent oral fentanyl dosage form and methods of administering fentanyl |
| JP2016029034A (ja) * | 2014-07-18 | 2016-03-03 | ナノメガ メディカル コーポレイションＮａｎｏｍｅｇａ Ｍｅｄｉｃａｌ Ｃｏｒｐｏｒａｔｉｏｎ | 医薬組成物 |
| JP2017203031A (ja) * | 2017-07-12 | 2017-11-16 | スティッチング グロニンゲン セントル フォー ドラッグ リサーチ | ｐＨ制御パルス送達システム、その調製法及び使用法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3131123A (en) * | 1959-03-13 | 1964-04-28 | Lab Francais De Therapeutique | Enteric tablets and manufacture thereof |
| FR2116256A1 (en) | 1970-12-02 | 1972-07-13 | Sobio Lab | Enteric - coated l-dopa - for treatment of parkinsonism with reduced gastrointestinal side-effects |
| US3891696A (en) * | 1973-11-02 | 1975-06-24 | Interx Research Corp | Novel, transient pro-drug forms of l-dopa |
-
1974
- 1974-11-14 JP JP49131304A patent/JPS5157813A/ja active Granted
-
1975
- 1975-04-10 US US05/566,745 patent/US3961041A/en not_active Expired - Lifetime
- 1975-11-10 GB GB46402/75A patent/GB1485676A/en not_active Expired
- 1975-11-13 ES ES442579A patent/ES442579A1/es not_active Expired
- 1975-11-13 CA CA239,591A patent/CA1047928A/en not_active Expired
- 1975-11-13 SE SE7512740A patent/SE7512740L/ not_active Application Discontinuation
- 1975-11-14 DE DE19752551280 patent/DE2551280A1/de not_active Withdrawn
- 1975-11-14 NL NL7513370A patent/NL7513370A/xx not_active Application Discontinuation
- 1975-11-14 FR FR7534769A patent/FR2290912A1/fr active Granted
- 1975-11-14 IT IT52218/75A patent/IT1069069B/it active
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2130087A (en) * | 1982-09-22 | 1984-05-31 | Dr Joachime Helbig | Pharmaceutical oral dosage forms of an active agent capable of forming or releasing bicarbonate ions |
| EP0228253A1 (en) * | 1985-12-30 | 1987-07-08 | Merck & Co. Inc. | Rectally absorbable form of L-dopa |
| US4786505A (en) * | 1986-04-30 | 1988-11-22 | Aktiebolaget Hassle | Pharmaceutical preparation for oral use |
| US4853230A (en) * | 1986-04-30 | 1989-08-01 | Aktiebolaget Hassle | Pharmaceutical formulations of acid labile substances for oral use |
| LT3699B (en) | 1986-04-30 | 1996-02-26 | Haessle Ab | Pharmaceutical preparation for oral use |
| US5286492A (en) * | 1990-05-03 | 1994-02-15 | Reckitt & Colman Products Limited | Method of treatment of Heliobacter pylori infections with triclosan |
| US6576258B1 (en) | 1997-07-14 | 2003-06-10 | Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. | Pharmaceutical formulation with controlled release of active substances |
| US6280773B1 (en) | 1998-12-29 | 2001-08-28 | Il Yang Pharm. Co., Ltd. | Optimally stabilized microgranule comprising 5-pyrrolyl-2-pyridylmethylsulfinylbenzimidazole derivative |
Also Published As
| Publication number | Publication date |
|---|---|
| IT1069069B (it) | 1985-03-25 |
| FR2290912B1 (enExample) | 1978-07-28 |
| JPS5436645B2 (enExample) | 1979-11-10 |
| JPS5157813A (en) | 1976-05-20 |
| CA1047928A (en) | 1979-02-06 |
| DE2551280A1 (de) | 1976-05-20 |
| SE7512740L (sv) | 1976-05-17 |
| US3961041A (en) | 1976-06-01 |
| FR2290912A1 (fr) | 1976-06-11 |
| NL7513370A (nl) | 1976-05-18 |
| ES442579A1 (es) | 1978-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB1485676A (en) | Pharmaceutical formulations containing l-dopa or derivatives thereof | |
| KR880012221A (ko) | 에스테르 또는 아미드를 활성성분으로 함유하는 약제 조성물 | |
| SE9402156L (sv) | Farmaceutiska kompositioner innehållande salterna av s(+)-2- (4-isobutylfenyl)-propionsyra med basiska aminosyror | |
| KR920019360A (ko) | 담즙산과 그 염을 함유하는 경구용 제어 방출 위 내성 의약 포뮬레이션 | |
| JPH10182456A (ja) | 高血圧治療用医薬組成物 | |
| NO150397C (no) | Analogifremgangsmaate for fremstilling av fysiologisk aktive acylderivater av aminosyrer | |
| ATE400242T1 (de) | Visköse zusammensetzungen mit kohlendioxid | |
| KR920019359A (ko) | 담즙산을 함유하는 경구용 위내성 의약 포뮬레이션 | |
| IL48835A (en) | Amino acyl and peptidyl derivatives of phophonic acids, their preparation and pharmaceutical compositions containingthem | |
| FR2314731A1 (fr) | Azacycloalcan-2-ones 1-substituees et compositions pharmaceutiques contenant ces composes a titre d'excipients | |
| ES465906A1 (es) | Un procedimiento de preparacion de comprimidos | |
| NO883261D0 (no) | Fremgangsmaate for fremstilling av et farmasoeytisk preparat | |
| NO140594C (no) | Analogifremgangsmaate for fremstilling av farmakologisk aktive n-(1-(omega-fenylalkyl)-piperidyl-4)-n-(alfa-pyridyl)-karboksylsyreamider | |
| ES461399A1 (es) | Procedimiento para preparar esteres de epinina con acidos carboxilicos de cadena ramificada. | |
| GB1388358A (en) | Taste-improving formulations of oral penicillins | |
| GB1416271A (en) | Psychopharmacologically active peptides | |
| SE8500965D0 (sv) | Mellanprodukter for framstellning av beta-laktamasinhibitorer | |
| GB1380904A (en) | Evaluation of pancreatic enzyme sufficiency | |
| NZ183117A (en) | Thio-ethers of clavulanic acid,salts,esters and pharmaceutical compositions | |
| IL47855A (en) | Pharmaceutical compositions containing cinnolin-3-yl carboxylic acids and ester amide derivatives therof some new compounds of htis type and processes for their preparation | |
| PT78939A (en) | Process for preparing esters of pantetheine and pantethine with 3-pyridineacetic or 3-(3-pyridylmethoxycarbonyl)-propionic acid and of pharmaceutical compositions containing the same | |
| SE394809B (sv) | Analogiforfarande for framstellning av antidepressivt verkande aralkylestrar av aminosyror | |
| ES435604A1 (es) | Procedimiento para la preparacion de derivados de indolila- cetilaminoacidos. | |
| GB1405949A (en) | Pharmaceutical preparations | |
| JPH0669476B2 (ja) | ゼラチン硬カプセルのフイルムコ−テイング方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed [section 19, patents act 1949] | ||
| PCNP | Patent ceased through non-payment of renewal fee |